Mean changes in cardiovascular risk factors and markers of endothelial activation
| Group | Mean (SD) at baseline | Mean (SD) at follow-up | Mean change | p Value comparing treatment groups* |
|---|---|---|---|---|
| hs-CRP (μg/ml) | ||||
| Atorvastatin (n=96) | 5.6 (8.5) | 4.6 (5.9) | −1.0 | 0.62 |
| Placebo (n=90) | 6.3 (9.2) | 4.5 (7.9) | −1.9 | |
| Lipoprotein (a) (mg/dl) | ||||
| Atorvastatin (n=96) | 66.7 (67.2) | 74.8 (70.7) | 8.1 | 0.044 |
| Placebo (n=90) | 67.1 (75.9) | 60.6 (69.0) | −6.6 | |
| Homocysteine (μM/l) | ||||
| Atorvastatin (n=96) | 12.2 (4.1) | 9.7 (3.4) | −2.5 | 0.55 |
| Placebo (n=90) | 11.9 (3.6) | 9.9 (3.5) | −2.0 | |
| ADMA (μM) | ||||
| Atorvastatin (n=75) | 0.33 (0.21) | 0.27 (0.20) | −0.06 | 0.24 |
| Placebo (n=70) | 0.28 (0.20) | 0.21 (0.19) | −0.07 | |
| Total cholesterol (mg/dl) | ||||
| Atorvastatin (n=99) | 181.6 (38.1) | 150.7 (40.7) | −30.8 | <0.0001 |
| Placebo (n=101) | 190.1 (36.9) | 195.6 (42.2) | 5.5 | |
| Interleukin 6 (pg/ml) | ||||
| Atorvastatin (n=95) | 2.1 (3.0) | 2.2 (3.0) | 0.1 | 0.37 |
| Placebo (n=91) | 2.4 (4.7) | 1.9 (2.7) | −0.5 | |
| Soluble P-selectin (ng/ml) | ||||
| Atorvastatin (n=95) | 108.7 (54.8) | 99.7 (51.7) | −9.0 | 0.60 |
| Placebo (n=91) | 105.9 (56.0) | 95.3 (47.6) | −10.6 | |
| Soluble intercellular adhesion molecule 1 (ng/ml) | ||||
| Atorvastatin (n=95) | 435.7 (235.8) | 471.8 (227.0) | 36.2 | 0.44 |
| Placebo (n=91) | 385.8 (144.4) | 454.5 (211.7) | 68.7 | |
| Soluble vascular cell adhesion molecule 1 (ng/ml) | ||||
| Atorvastatin (n=95) | 1066.5 (632.2) | 1113.1 (617.5) | 46.6 | 0.63 |
| Placebo (n=91) | 1046.0 (613.9) | 1133.7 (630.7) | 87.7 | |
↵* Based on an ANCOVA model controlling for baseline level.
ADMA, asymmetric dimethyl arginine.